JTE-013 (gavage;30mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model: Six-week-old female athymic NCr-nu/nu nude mice. Dosage: 30mg/kg Administration: Gavage;daily for 14 consecutive days Result: ...
JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model: Six-week-old female athymic NCr-nu/nu nude mice Dosage: 30 mg/kg Administration: Gavage; daily for 14 consecutive days Result: Reduced tumor size and tumor weight. 分子式 C17...
JTE-013 CAS号: 383150-41-2 英文名: JTE-013 英文别名: CS-2553;JTE-013 HCl;JTE-013;JTE 013;JTE013;JTE-013, 10 mM in DMSO;LPL Receptor,Apoptosis,JTE-013,Inhibitor,Lysophospholipid Receptor,JTE 013,inhibit,JTE013;1-(2,6-dichloro-4-pyridyl)-3-[(4-isopropyl-1,3-dimethyl-pyrazolo[...
Orally administered JTE-907 (0.1–10 mg/kg) and SR144528 (1 mg/kg) also produced significant inhibition of dinitrofluorobenzene-induced ear swelling, with increased cannabinoid CB2 receptor mRNA expression observed in the inflamed ear. These results suggest that cannabinoid CB2 receptor is partially...
Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 2005; 520:164-71.Ueda Y, Miyagawa N, Matsui T et al. Involvement of cannabinoid CB(2) recep- tor-mediated ...
Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (2005). Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 520: 164-171....